CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.3M, lower than 95% of all stocks globally
- PositionOperating margin is -9465.5%, lower than 95% of its Biotechnology peers (median -34.2%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.28BUSDvs all stocks (USD)
Revenue (TTM)
1.30MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
3.43xvs all stocks
52-Week Change
295.07%vs all stocks
Market Capitalization
1.28BUSDvs all stocks (USD)
Enterprise Value
1.30BUSDvs all stocks (USD)
Forward P/E
-13.87xvs Biotechnology peers
Enterprise to Revenue
1.00Kxvs Biotechnology peers
Enterprise to EBITDA
-10.78xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-36.06%vs Biotechnology peers
Revenue (TTM)
1.30MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0840USDUpdated Jul 19, 2026Gross Profit (TTM)
-100.07MUSDvs all stocks (USD)
EBITDA (TTM)
-120.71MUSDvs all stocks (USD)
Net Income (TTM)
-130.19MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-131.93MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.11MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.30MUSDFY2025 · Dec 31, 2025Operating Income
-135.03MUSDvs all stocks (USD)
Pre-tax Income
-140.05MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.00KUSDFY2025 · Dec 31, 2025Net Income
-140.06MUSDFY2025 · Dec 31, 2025EBIT
-127.86MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-125.37MUSDFY2025 · Dec 31, 2025Research & Development
113.03MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
12.20MUSDFY2025 · Dec 31, 2025EPS (Basic)
-9.04USDFY2025 · Dec 31, 2025EPS (Diluted)
-9.04USDFY2025 · Dec 31, 2025Basic Shares Outstanding
15.49MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
15.49MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-140.06MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-126.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-126.87MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.48M of depreciation against 28K of capital expenditure, and its own free-cash-flow line reads -129.83M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
124.22MUSDFY2025 · Dec 31, 2025Income Tax Paid
2.00KUSDFY2025 · Dec 31, 2025Interest Paid
8.90MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-140.06MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.48MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.14MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.24MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
243.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.30MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.59MUSDFY2025 · Dec 31, 2025Capital Expenditures
-28.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-28.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
99.97MUSDFY2025 · Dec 31, 2025Other Financing Charges
-125.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
99.84MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.61MSharesUpdated Jul 19, 2026Float Shares
8.37MSharesUpdated Jul 19, 2026Shares Short
3.45MSharesUpdated Jul 19, 2026Short Ratio
10.24daysvs all stocks
Short % of Shares Outstanding
31.40%vs all stocks
% Held by Insiders
23.16%vs all stocks
% Held by Institutions
82.24%vs all stocks
Total Cash (MRQ)
161.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
11.02USDUpdated Jul 19, 2026Total Debt (MRQ)
180.90MUSDvs all stocks (USD)
Current Ratio (MRQ)
6.46xvs Biotechnology peers
Book Value per Share (MRQ)
-1.44USDUpdated Jul 19, 2026Total Assets
146.48MUSDvs all stocks (USD)
Total Current Assets
132.83MUSDFY2025 · Dec 31, 2025Total Liabilities
138.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
13.65MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
104.69MUSDFY2025 · Dec 31, 2025Total Current Liabilities
33.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
124.22MUSDFY2025 · Dec 31, 2025Accounts Receivable
0.00USDFY2025 · Dec 31, 2025Accounts Payable
5.94MUSDFY2025 · Dec 31, 2025Short-term Debt
2.33MUSDFY2025 · Dec 31, 2025Long-term Debt
104.69MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-246.19MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
7.99MUSDvs all stocks (USD)
52-Week Low
20.55USDUpdated Jul 19, 202652-Week High
155.29USDUpdated Jul 19, 202652-Week Change
295.07%vs all stocks
Beta
3.43xvs all stocks
50-Day MA
100.55USDUpdated Jul 19, 2026200-Day MA
81.34USDUpdated Jul 19, 2026Avg 10-Day Volume
389.14KSharesUpdated Jul 19, 2026Avg 30-Day Volume
351.83KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-8.39USDUpdated Jul 19, 2026Other Income / Expense
-381.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -9465.5%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -94.65Industry median: -0.34Industry P5: -43.55Peers compared: 261
Financial Health
Altman Z-Score 1.14: grey zoneSignificant
Altman Z-Score: 1.14
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.3M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,300,000Global P5: 30,274,777.221
Market cap is $1.28B, above the global median of $1.15BNotable
Market cap (USD): 1,282,114,944Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk